151 related articles for article (PubMed ID: 38574468)
1. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia.
Nasnas PE; Jabbour EJ; Sasaki K; Issa GC; Masarova L; Short NJ; Haddad FG
Acta Haematol; 2024 Apr; ():. PubMed ID: 38574468
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
3. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG; Deininger MW
Blood Rev; 2021 Sep; 49():100825. PubMed ID: 33773846
[TBL] [Abstract][Full Text] [Related]
4. Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
Etienne G; Dulucq S; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Madene S; Fort MP; Bijou F; Moldovan M; Turcq B; Robbesyn F; Durrieu F; Versmée L; Katsahian S; Faberes C; Lascaux A; Mahon FX
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899879
[No Abstract] [Full Text] [Related]
5. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
6. Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):785-790. PubMed ID: 32768385
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Free Remission: the New Goal in CML Therapy.
Atallah E; Sweet K
Curr Hematol Malig Rep; 2021 Oct; 16(5):433-439. PubMed ID: 34618317
[TBL] [Abstract][Full Text] [Related]
9. Treatment-free remission and immunity in chronic myeloid leukemia.
Ureshino H
Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
[TBL] [Abstract][Full Text] [Related]
10. Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice.
Boquimpani C; Seguro FS; Magalhães GHR; Pinto ILS; Bendit I; Bortolini JAP; Pagnano KBB; Centrone R; Funke V
Hematol Transfus Cell Ther; 2022; 44(3):402-409. PubMed ID: 35654721
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?
Çiftçiler R; Akın MG; Erat Z; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):8-14. PubMed ID: 36344420
[TBL] [Abstract][Full Text] [Related]
13. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
Yu L; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
[No Abstract] [Full Text] [Related]
14. Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.
Jun K; Ya-Zhen Q; Xiao-Su Z; Hong-Xia S; Yue-Yun L; Kai-Yan L; Xiao-Jun H; Hao J
Ther Adv Hematol; 2021; 12():2040620720986643. PubMed ID: 33613929
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson S; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Pane F; Nicolini FE; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
Leuk Lymphoma; 2020 Mar; 61(3):650-659. PubMed ID: 31647335
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
17. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
Dulucq S; Mahon FX
Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039
[TBL] [Abstract][Full Text] [Related]
18. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
19. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
Takahashi N; Tauchi T; Kitamura K; Miyamura K; Saburi Y; Hatta Y; Miyata Y; Kobayashi S; Usuki K; Matsumura I; Minami Y; Usui N; Fukuda T; Takada S; Ishikawa M; Fujimaki K; Gomyo H; Sasaki O; Ohishi K; Miyake T; Imai K; Suzushima H; Mitsui H; Togitani K; Kiguchi T; Atsuta Y; Ohtake S; Ohnishi K; Kobayashi Y; Kiyoi H; Miyazaki Y; Naoe T;
Int J Hematol; 2018 Feb; 107(2):185-193. PubMed ID: 28929332
[TBL] [Abstract][Full Text] [Related]
20. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
